A growing aging population and increased prevalence of neurological disorders in the region contributes to North America’s dominance in antipsychotic sales in the global market, and sales of these drugs is expected to grow at a significant rate through 2021, according to market research company Persistence Market Research
Antipsychotics are a group of medicines that are used to treat mental illnesses such as schizophrenia, schizoaffective disorder, bipolar disorder, and psychotic depression. They are also used to treat severe depression, anxiety, autism, and other behavioral conditions including ADHD.
A growing awareness regarding different neurological disorders and their available treatment are expected to help boost the global market for antipsychotics, as is improvement in health care facilities and technological advances in the field of neurology. But factors such as side effects and lower adoption rate have been hurting market growth.
One of the more common atypical antipsychotic drugs is Risperdal, known chemically as risperidone. The drug is used to treat adults and children with schizophrenia, bipolar disorder and irritability with autism. Studies have shown that Risperdal can increase levels of prolactin in the body.
Prolactin is the hormone responsible for triggering lactation in pregnant women. When this hormone is elevated in adolescent boys, it can cause the growth of breast tissue, a condition known as gynecomatia.
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals are facing thousands of lawsuits alleging the companies did not adequately warn consumers about Risperdal side effects, including disfiguring gynecomastia.
Source: Digital Journal